Terbutaline, A β2-Adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs

Masafumi Kogire, Masaaki Izukura, Guillermo Gomez, Tatsuo Uchida, George H. Greeley, James C. Thompson

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Terbutaline, a β2-adrenoreceptor agonist, inhibits pentagastrin-stimulated gastric acid secretion. The purpose of this study was to examine the effect of intravenous administration of terbutaline on plasma levels of peptide YY(PYY) and gastric inhibitory polypeptide (GIP), both of which are known to inhibit gastric acid secretion. Seven dogs with gastric and duodenal fistulas were given pentagastrin (1 μg/kg/hr) intravenously for 150 min in combination with terbutaline (10 or 20 μg/kg/hr) or saline during the 60- to 120-min period of pentagastrin infusion. Pentagastrin-stimulated gastric acid secretion was significantly (P <0.05) inhibited by intravenous administration of terbutaline. Terbutaline significantly increased plasma PYY levels, 24% in response to terbutaline at 10 μg/kg/hr, and 59% at 20 μg/kg/hr. Plasma GIP levels were also increased significantly, 24% with terbutaline at 10 μg/kg/hr, and 39% at 20 μg/kg/hr. Our data suggest that terbutaline-induced inhibition of pentagastrin-stimulated gastric acid secretion is mediated, at least in part, by the release of PYY and GIP. The adrenergic nervous system may influence gastric acid secretion through the release of PYY and GIP.

Original languageEnglish (US)
Pages (from-to)453-457
Number of pages5
JournalDigestive Diseases and Sciences
Volume35
Issue number4
DOIs
StatePublished - Apr 1990

Fingerprint

Gastric Inhibitory Polypeptide
Peptide YY
Terbutaline
Gastric Acid
varespladib methyl
Pentagastrin
Dogs
Intravenous Administration
Gastric Fistula
Adrenergic Agents
Nervous System

Keywords

  • acid secretion
  • dog
  • gastric inhibitory polypeptide
  • peptide YY
  • terbutaline

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Terbutaline, A β2-Adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs. / Kogire, Masafumi; Izukura, Masaaki; Gomez, Guillermo; Uchida, Tatsuo; Greeley, George H.; Thompson, James C.

In: Digestive Diseases and Sciences, Vol. 35, No. 4, 04.1990, p. 453-457.

Research output: Contribution to journalArticle

Kogire, Masafumi ; Izukura, Masaaki ; Gomez, Guillermo ; Uchida, Tatsuo ; Greeley, George H. ; Thompson, James C. / Terbutaline, A β2-Adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs. In: Digestive Diseases and Sciences. 1990 ; Vol. 35, No. 4. pp. 453-457.
@article{40d4543c774b4f6da1e9d51b735e28af,
title = "Terbutaline, A β2-Adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs",
abstract = "Terbutaline, a β2-adrenoreceptor agonist, inhibits pentagastrin-stimulated gastric acid secretion. The purpose of this study was to examine the effect of intravenous administration of terbutaline on plasma levels of peptide YY(PYY) and gastric inhibitory polypeptide (GIP), both of which are known to inhibit gastric acid secretion. Seven dogs with gastric and duodenal fistulas were given pentagastrin (1 μg/kg/hr) intravenously for 150 min in combination with terbutaline (10 or 20 μg/kg/hr) or saline during the 60- to 120-min period of pentagastrin infusion. Pentagastrin-stimulated gastric acid secretion was significantly (P <0.05) inhibited by intravenous administration of terbutaline. Terbutaline significantly increased plasma PYY levels, 24{\%} in response to terbutaline at 10 μg/kg/hr, and 59{\%} at 20 μg/kg/hr. Plasma GIP levels were also increased significantly, 24{\%} with terbutaline at 10 μg/kg/hr, and 39{\%} at 20 μg/kg/hr. Our data suggest that terbutaline-induced inhibition of pentagastrin-stimulated gastric acid secretion is mediated, at least in part, by the release of PYY and GIP. The adrenergic nervous system may influence gastric acid secretion through the release of PYY and GIP.",
keywords = "acid secretion, dog, gastric inhibitory polypeptide, peptide YY, terbutaline",
author = "Masafumi Kogire and Masaaki Izukura and Guillermo Gomez and Tatsuo Uchida and Greeley, {George H.} and Thompson, {James C.}",
year = "1990",
month = "4",
doi = "10.1007/BF01536919",
language = "English (US)",
volume = "35",
pages = "453--457",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Terbutaline, A β2-Adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs

AU - Kogire, Masafumi

AU - Izukura, Masaaki

AU - Gomez, Guillermo

AU - Uchida, Tatsuo

AU - Greeley, George H.

AU - Thompson, James C.

PY - 1990/4

Y1 - 1990/4

N2 - Terbutaline, a β2-adrenoreceptor agonist, inhibits pentagastrin-stimulated gastric acid secretion. The purpose of this study was to examine the effect of intravenous administration of terbutaline on plasma levels of peptide YY(PYY) and gastric inhibitory polypeptide (GIP), both of which are known to inhibit gastric acid secretion. Seven dogs with gastric and duodenal fistulas were given pentagastrin (1 μg/kg/hr) intravenously for 150 min in combination with terbutaline (10 or 20 μg/kg/hr) or saline during the 60- to 120-min period of pentagastrin infusion. Pentagastrin-stimulated gastric acid secretion was significantly (P <0.05) inhibited by intravenous administration of terbutaline. Terbutaline significantly increased plasma PYY levels, 24% in response to terbutaline at 10 μg/kg/hr, and 59% at 20 μg/kg/hr. Plasma GIP levels were also increased significantly, 24% with terbutaline at 10 μg/kg/hr, and 39% at 20 μg/kg/hr. Our data suggest that terbutaline-induced inhibition of pentagastrin-stimulated gastric acid secretion is mediated, at least in part, by the release of PYY and GIP. The adrenergic nervous system may influence gastric acid secretion through the release of PYY and GIP.

AB - Terbutaline, a β2-adrenoreceptor agonist, inhibits pentagastrin-stimulated gastric acid secretion. The purpose of this study was to examine the effect of intravenous administration of terbutaline on plasma levels of peptide YY(PYY) and gastric inhibitory polypeptide (GIP), both of which are known to inhibit gastric acid secretion. Seven dogs with gastric and duodenal fistulas were given pentagastrin (1 μg/kg/hr) intravenously for 150 min in combination with terbutaline (10 or 20 μg/kg/hr) or saline during the 60- to 120-min period of pentagastrin infusion. Pentagastrin-stimulated gastric acid secretion was significantly (P <0.05) inhibited by intravenous administration of terbutaline. Terbutaline significantly increased plasma PYY levels, 24% in response to terbutaline at 10 μg/kg/hr, and 59% at 20 μg/kg/hr. Plasma GIP levels were also increased significantly, 24% with terbutaline at 10 μg/kg/hr, and 39% at 20 μg/kg/hr. Our data suggest that terbutaline-induced inhibition of pentagastrin-stimulated gastric acid secretion is mediated, at least in part, by the release of PYY and GIP. The adrenergic nervous system may influence gastric acid secretion through the release of PYY and GIP.

KW - acid secretion

KW - dog

KW - gastric inhibitory polypeptide

KW - peptide YY

KW - terbutaline

UR - http://www.scopus.com/inward/record.url?scp=0025219065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025219065&partnerID=8YFLogxK

U2 - 10.1007/BF01536919

DO - 10.1007/BF01536919

M3 - Article

C2 - 2156661

AN - SCOPUS:0025219065

VL - 35

SP - 453

EP - 457

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 4

ER -